MaaT Pharma Presents Positive Results with Lead Product MaaT013 and Provides Insights on Ongoing Phase 2b Trial with MaaT033 at ASH 2023
Positive efficacy and good safety results from 111 patients with acute graft-versus-host disease (aGvHD) treated with MaaT013 in Early Access Program presented... Read more.
Fanttik Electric Screwdrivers Dominate TikTok Shop during Black Friday, Foreshadowing Christmas Sales
HOUSTON–(BUSINESS WIRE)–Fanttik hit several brilliant milestones with its range of electric screwdrivers during this year’s Black Friday sales, generating... Read more.
Tire Inflator Expert Fanttik Redefines Its Tire Inflator Products for Christmas 2023
HOUSTON–(BUSINESS WIRE)–Fanttik, the trailblazing award-winning brand in the automotive accessories industry, is proud to announce its remarkable achievements... Read more.
KuCoin Labs Invests in Dovi, a Bitcoin L2 Solution, to Further Advance the Development of BTC Ecosystem
VICTORIA, Seychelles–(BUSINESS WIRE)–#blockchain—KuCoin Labs, the incubator and investment arm of the KuCoin ecosystem, has once again demonstrated... Read more.
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
Collaboration leverages the proven development and commercial capability of Ferring with PharmaBiome’s compelling technology to research, develop and manufacture... Read more.
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
SAR443579/IPH6101, ANKET® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between... Read more.
ASE Technology Holding Co., Ltd Receives Industry Leadership Recognition on the Dow Jones Sustainability Indices for the Eighth Year in a Row
The only semiconductor company in the world to secure the highest ESG scores in the Semiconductor and Semi Equipment Industry Group KAOHSIUNG, Taiwan–(BUSINESS... Read more.
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
In TRANSCEND FL, 95.7% of patients with high-risk relapsed or refractory follicular lymphoma (FL) treated with Breyanzi in the second-line setting achieved a complete... Read more.
Mitsubishi Electric and TXOne Networks to Cooperate in Mutual Expansion of OT Security Businesses
TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation and TXOne Networks Inc. announced today that they have signed a long-term cooperation agreement... Read more.
Boosting Business Acumen: Chicago Booth’s Executive Education Program in Finance Workshop for Non-Financial Leaders–Available in Hong Kong and Chicago
CHICAGO–(BUSINESS WIRE)–#ChicagoBoothExecEd–The University of Chicago Booth School of Business introduces The Chicago Booth Approach to Finance... Read more.